Document is current
Any future updates will be listed below
-
Authors
Bhimani, Jenna
O’Connell, Kelli
Persaud, Sonia
Blinder, Victoria
Burganowski, Rachael P.
Ergas, Isaac J.
Gallagher, Grace B.
Griggs, Jennifer J.
Heon, Narre
Kolevska, Tatjana
Kotsurovskyy, Yuriy
Kroenke, Candyce H.
Laurent, Cecile. A.
Liu, Raymond
Nakata, Kanichi G.
Rivera, Donna R.
Roh, Janise M.
Tabatabai, Sara
Valice, Emily
Bandera, Elisa V.
Aiello Bowles, Erin J.
Kushi, Lawrence H.
Kantor, Elizabeth D.
-
Funding
Funding for this research was provided by:
National Cancer Institute of the National Institute of Health, United States (R50CA211115, U24CA171524, U24CA171524)
National Cancer Institute (P01CA154292)
Geoffrey Beene Cancer Research Center
- License Information
-
More Information
Article History
Received: 3 April 2024
Accepted: 7 July 2024
First Online: 16 August 2024
Declarations
:
: Dr. Bandera served as member of Pfizer’s Advisory Board to enhance minority participation in clinical trials (8/2002-8/2023). Dr. Liu served as member of Pfizer’s think tank on real-world evidence sponsored by Pfizer on 11/28/23. Dr. Liu’s research funding (inst) unrelated to this current work: Genentech, AstraZeneca, Exact Sciences, Biotheranostics, and BeiGene. Other authors have no COI to declare.
: IRB approval was obtained from Memorial Sloan Kettering Cancer Center, Rutgers University, KPNC, and KPWA, with a waiver of consent to extract and analyze patient data at KPNC and KPWA.
